Intellia Therapeutics

Home » Intellia Therapeutics

Secondary

Intellia Therapeutics

They are a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as CRISPR/Cas9.

Symbol

NTLA

Last Closing Price
$18.30

Shares
1,520,000

Effective Date
December 13, 2017

Underwriters
UBS

To view the prospectus for Intellia Therapeutics, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253